4,5-Dehydro-L-leucine
Need Assistance?
  • US & Canada:
    +
  • UK: +

4,5-Dehydro-L-leucine

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
L-Amino Acids
Catalog number
BAT-007848
CAS number
87392-13-0
Molecular Formula
C6H11NO2
Molecular Weight
129.16
4,5-Dehydro-L-leucine
IUPAC Name
(2S)-2-amino-4-methylpent-4-enoic acid
Synonyms
H-Leu(4,5-dehydro)-OH; L-Methylallylglycine; 4,5-DEHYDRO-LEUCINE; 4-Pentenoic acid, 2-amino-4-methyl-, (2S)-; (S)-2-amino-4-methylpent-4-enoic acid; (2S)-2-amino-4-methyl-4-pentenoic acid; H-4,5-Dehydro-Leu-OH; (S)-2-Methallylglycine; (2S)-2-amino-4-methylpent-4-enoic acid; 4,5-didehydro-l-leucine
Purity
≥ 99%
Storage
Store at 2-8 °C
InChI
InChI=1S/C6H11NO2/c1-4(2)3-5(7)6(8)9/h5H,1,3,7H2,2H3,(H,8,9)/t5-/m0/s1
InChI Key
PABWDKROPVYJBH-YFKPBYRVSA-N
Canonical SMILES
CC(=C)CC(C(=O)O)N
1. Genetic basis for the biosynthesis of the pharmaceutically important class of epoxyketone proteasome inhibitors
Michelle Schorn, Judith Zettler, Joseph P Noel, Pieter C Dorrestein, Bradley S Moore, Leonard Kaysser ACS Chem Biol. 2014 Jan 17;9(1):301-9. doi: 10.1021/cb400699p. Epub 2013 Nov 8.
The epoxyketone proteasome inhibitors are an established class of therapeutic agents for the treatment of cancer. Their unique α',β'-epoxyketone pharmacophore allows binding to the catalytic β-subunits of the proteasome with extraordinary specificity. Here, we report the characterization of the first gene clusters for the biosynthesis of natural peptidyl-epoxyketones. The clusters for epoxomicin, the lead compound for the anticancer drug Kyprolis, and for eponemycin were identified in the actinobacterial producer strains ATCC 53904 and Streptomyces hygroscopicus ATCC 53709, respectively, using a modified protocol for Ion Torrent PGM genome sequencing. Both gene clusters code for a hybrid nonribosomal peptide synthetase/polyketide synthase multifunctional enzyme complex and homologous redox enzymes. Epoxomicin and eponemycin were heterologously produced in Streptomyces albus J1046 via whole pathway expression. Moreover, we employed mass spectral molecular networking for a new comparative metabolomics approach in a heterologous system and discovered a number of putative epoxyketone derivatives. With this study, we have definitively linked epoxyketone proteasome inhibitors and their biosynthesis genes for the first time in any organism, which will now allow for their detailed biochemical investigation.
2. Identifying the Minimal Enzymes Required for Biosynthesis of Epoxyketone Proteasome Inhibitors
Joyce Liu, Xuejun Zhu, Wenjun Zhang Chembiochem. 2015 Dec;16(18):2585-9. doi: 10.1002/cbic.201500496. Epub 2015 Nov 2.
Epoxyketone proteasome inhibitors have attracted much interest due to their potential as anticancer drugs. Although the biosynthetic gene clusters for several peptidyl epoxyketone natural products have recently been identified, the enzymatic logic involved in the formation of the terminal epoxyketone pharmacophore has been relatively unexplored. Here, we report the identification of the minimal set of enzymes from the eponemycin gene cluster necessary for the biosynthesis of novel metabolites containing a terminal epoxyketone pharmacophore in Escherichia coli, a versatile and fast-growing heterologous host. This set of enzymes includes a non-ribosomal peptide synthetase (NRPS), a polyketide synthase (PKS), and an acyl-CoA dehydrogenase (ACAD) homologue. In addition to the in vivo functional reconstitution of these enzymes in E. coli, in vitro studies of the eponemycin NRPS and (13) C-labeled precursor feeding experiments were performed to advance the mechanistic understanding of terminal epoxyketone formation.
3. Production of Epoxyketone Peptide-Based Proteasome Inhibitors by Streptomyces sp. BRA-346: Regulation and Biosynthesis
Bruna Domingues Vieira, et al. Front Microbiol. 2022 Mar 24;13:786008. doi: 10.3389/fmicb.2022.786008. eCollection 2022.
Streptomyces sp. BRA-346 is an Actinobacteria isolated from the Brazilian endemic tunicate Euherdmania sp. We have reported that this strain produces epoxyketone peptides, as dihydroeponemycin (DHE) and structurally related analogs. This cocktail of epoxyketone peptides inhibits the proteasome chymotrypsin-like activity and shows high cytotoxicity to glioma cells. However, low yields and poor reproducibility of epoxyketone peptides production by BRA-346 under laboratory cultivation have limited the isolation of epoxyketone peptides for additional studies. Here, we evaluated several cultivation methods using different culture media and chemical elicitors to increase the repertoire of peptide epoxyketone production by this bacterium. Furthermore, BRA-346 genome was sequenced, revealing its broad genetic potential, which is mostly hidden under laboratory conditions. By using specific growth conditions, we were able to evidence different classes of secondary metabolites produced by BRA-346. In addition, by combining genome mining with untargeted metabolomics, we could link the metabolites produced by BRA-346 to its genetic capacity and potential regulators. A single biosynthetic gene cluster (BGC) was related to the production of the target epoxyketone peptides by BRA-346. The candidate BGC displays conserved biosynthetic enzymes with the reported eponemycin (EPN) and TMC-86A (TMC) BGCs. The core of the putative epoxyketone peptide BGC (ORFs A-L), in which ORF A is a LuxR-like transcription factor, was cloned into a heterologous host. The recombinant organism was capable to produce TMC and EPN natural products, along with the biosynthetic intermediates DH-TMC and DHE, and additional congeners. A phylogenetic analysis of the epn/tmc BGC revealed related BGCs in public databases. Most of them carry a proteasome beta-subunit, however, lacking an assigned specialized metabolite. The retrieved BGCs also display a diversity of regulatory genes and TTA codons, indicating tight regulation of this BGC at the transcription and translational levels. These results demonstrate the plasticity of the epn/tmc BGC of BRA-346 in producing epoxyketone peptides and the feasibility of their production in a heterologous host. This work also highlights the capacity of BRA-346 to tightly regulate its secondary metabolism and shed light on how to awake silent gene clusters of Streptomyces sp. BRA-346 to allow the production of pharmacologically important biosynthetic products.
Online Inquiry
Verification code
Inquiry Basket